Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada

Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhanced in vitro activi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Patel, Samir N., McGeer, Allison, Melano, Roberto, Tyrrell, Gregory J., Green, Karen, Pillai, Dylan R., Low, Donald E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2011
Gaiak:
Epidemiology and Surveillance
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147653/
https://ncbi.nlm.nih.gov/pubmed/21628545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00237-11
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak